SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 25, Issue 33, 2007, Pages 5333-5334

The value meal: Effect of food on lapatinib bioavailability [10]

(5) Rahman, Atiqur a Pazdur, Richard a Wang, Yaning a Huang, Shiew Mei a Lesko, Lawrence a

a CENTER FOR DRUG EVALUATION AND RESEARCH (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAPATINIB; LOPINAVIR; RITONAVIR; TIPRANAVIR;

BREAST CANCER; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; FOOD; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; HUMAN; LETTER; LIPID DIET; PRIORITY JOURNAL; UNITED STATES;

ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; FOOD-DRUG INTERACTIONS; HUMANS; QUINAZOLINES;

EID: 36849078567 PISSN: 0732183X EISSN: None Source Type: Journal
DOI: 10.1200/JCO.2007.14.6381 Document Type: Letter

Times cited : (15)

References (8)

1
- 34548178015
- The value meal: How to save $1,700 per month or more on Lapatinib
- Ratain MJ, Cohen EE: The value meal: How to save $1,700 per month or more on Lapatinib. J Clin Oncol 25:3397-3398, 2007
- (2007) J Clin Oncol , vol.25 , pp. 3397-3398
- Ratain, M.J.¹ Cohen, E.E.²

2
- 67749135622
- Tykerb Label. http://www.fda.gov/cder/foi/label/2007/022059s001lbl.pdf
- Tykerb Label

3
- 34548167457
- A phase I, open-label, three period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients
- Reddy N, Cohen R, Whitehead B, et al: A phase I, open-label, three period, randomized crossover study to evaluate the effect of food on the pharmacokinetics of lapatinib in cancer patients. Clin Pharmacol Ther 81:S16-S17, 2007
- (2007) Clin Pharmacol Ther , vol.81
- Reddy, N.¹ Cohen, R.² Whitehead, B.³

4
- 84871473365
- Women Fitness: Nutrition of the Cancer Patients. http://www.womenfitness. net/programs/nutrition/nutrition.htm
- Women Fitness: Nutrition of the Cancer Patients

5
- 84871470007
- Invirase Label. http://www.fda.gov/cder/foi/label/2007/020628s025, 021785s004lbl.pdf
- Invirase Label. http://www.fda.gov/cder/foi/label/2007/020628s025, 021785s004lbl.pdf

6
- 84871470256
- Kaletra Label. http://www.fda.gov/cder/foi/label/2007/021251s016, 021906s005lbl.pdf
- Kaletra Label. http://www.fda.gov/cder/foi/label/2007/021251s016, 021906s005lbl.pdf

7
- 33846577441
- Drug-drug interactions: Study design, data analysis and implications for dosing recommendations
- Huang S-M, Temple R, Throckmorton DD, et al: Drug-drug interactions: Study design, data analysis and implications for dosing recommendations, Clin Pharmacol Ther 81:298-304, 2007
- (2007) Clin Pharmacol Ther , vol.81 , pp. 298-304
- Huang, S.-M.¹ Temple, R.² Throckmorton, D.D.³

8
- 85056953781
- Huang S-M, Temple R, Lesko LJ: Drug-Drug, drug-dietary supplement, and drug-citrus fruit and other food interactions - labeling implications, in Lam F, Huang S-M, Hall SD (eds): Herbal Supplements-Drug Interactions. New York, NY, Informa Healthcare, 2006
- Huang S-M, Temple R, Lesko LJ: Drug-Drug, drug-dietary supplement, and drug-citrus fruit and other food interactions - labeling implications, in Lam F, Huang S-M, Hall SD (eds): Herbal Supplements-Drug Interactions. New York, NY, Informa Healthcare, 2006

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.